Tuesday, 13 October 20266:25 pm ISTIndia edition

सच, सीधे आप तक

Book ad space

Just in

India

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Image: Asianet Newsable. Rights remain with the publisher.

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis.

Read the full report on Asianet Newsable

Story file

Section
India
First reported by
Asianet Newsable
Reporter
stocktwits inc
Published
Tuesday, 13 October 2026, 4:00 am IST
Coverage
One outlet so far

How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

Related stories

More India news

See all